Histopathologic and clinical outcome of
β
Iva Gunnarsson; Birgitta Sundelin; Thorunn JΓ³nsdΓ³ttir; Stefan H. Jacobson; Elisa
π
Article
π
2007
π
John Wiley and Sons
π
English
β 106 KB
π 2 views
## Abstract ## Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells. Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be of benefit in B cellβdependent diseases, including systemic lupus erythematosus (SLE). The purpose